313- Feagan B. Update on tofacitinib for inflammatory bowel disease. Gastroenterol Hepatol (N Y).
2016;12:572–4. - Sandborn WJ, Sands BE, D'Haens G, et al. Efficacy and safety of oral tofacitinib as induc-
tion therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 ran-
domised controlled trials. J Crohns Colitis. 2016;10:S15-S. - Sandborn W, Sands B, Danese S, et al. Efficacy and safety of oral tofacitinib as maintenance
therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised
controlled trial. J Crohns Colitis. 2017;10:S15-S. - Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance ther-
apy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut.
2017;66(6):1049–59. - Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-
severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2,
double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–75. - Ardizzone S, Bevivino G, Monteleone G. Mongersen, an oral Smad7 antisense oligonucle-
otide, in patients with active Crohn’s disease. Therap Adv Gastroenterol. 2016;9:527–32. - Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligo-
nucleotide, and Crohn’s disease. N Engl J Med. 2015;372:1104–13. - Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking
Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest.
2001;108:601–9. - Vermeire S. Oral SMAD7 antisense drug for Crohn’s disease. N Engl J Med. 2015;372:1166–7.
17 Novel Agents in Inflammatory Bowel Disease